Natural Variants of the KPC-2 Carbapenemase have Evolved Increased Catalytic Efficiency for Ceftazidime Hydrolysis at the Cost of Enzyme Stability

Shrenik C. Mehta, Kacie Rice, Timothy Palzkill *
Department of Pharmacology, Baylor College of Medicine, Houston, Texas, United States of America
* timothyp@bcm.edu

Abstract

The spread of β-lactamases that hydrolyze penicillins, cephalosporins and carbapenems among Gram-negative bacteria has limited options for treating bacterial infections. Initially, Klebsiella pneumoniae carbapenemase-2 (KPC-2) emerged as a widespread carbapenem hydrolyzing β-lactamase that also hydrolyzes penicillins and cephalosporins but not cephamycins and ceftazidime. In recent years, single and double amino acid substitution variants of KPC-2 have emerged among clinical isolates that show increased resistance to ceftazidime. Because it confers multi-drug resistance, KPC β-lactamase is a threat to public health.

In this study, the evolution of KPC-2 function was determined in nine clinically isolated variants by examining the effects of the substitutions on enzyme kinetic parameters, protein stability and antibiotic resistance profile. The results indicate that the amino acid substitutions associated with KPC-2 natural variants lead to increased catalytic efficiency for ceftazidime hydrolysis and a consequent increase in ceftazidime resistance. Single substitutions lead to modest increases in catalytic activity while the double mutants exhibit significantly increased ceftazidime hydrolysis and resistance levels. The P104R, V240G and H274Y substitutions in single and double mutant combinations lead to the largest increases in ceftazidime hydrolysis and resistance. Molecular modeling suggests that the P104R and H274Y mutations could facilitate ceftazidime hydrolysis through increased hydrogen bonding interactions with the substrate while the V240G substitution may enhance backbone flexibility so that larger substrates might be accommodated in the active site. Additionally, we observed a strong correlation between gain of catalytic function for ceftazidime hydrolysis and loss of enzyme stability, which is in agreement with the ‘stability-function tradeoff’ phenomenon. The high Tm of KPC-2 (66.5°C) provides an evolutionary advantage as compared to other class A enzymes such as TEM (51.5°C) and CTX-M (51°C) in that it can acquire multiple destabilizing substitutions without losing the ability to fold into a functional enzyme.
Author Summary

The absence of new antibiotics combined with the emergence of antibiotic-resistance enzymes like KPC-2 that can inactivate most β-lactam antibiotics has resulted in a longer duration of medical treatment, higher costs of medical care, and increased mortality. In recent years, a number of amino acid sequence variants of KPC-2 have been identified in clinical isolates worldwide suggesting continued evolution of resistance in KPC-2. In this study we have characterized nine clinically isolated variants of KPC-2 (KPC-3 to -11) that differ from the initial KPC-2 isolate by one to two amino acids. The KPC variants confer increased resistance to the antibiotic ceftazidime as compared to KPC-2. This increase in resistance is correlated with improved ability of the variant enzymes to hydrolyze the antibiotic. Additionally, the changes associated with increased ceftazidime hydrolysis also reduce the thermal stability of the enzyme, indicating the mutations that assist catalysis come with a cost on the overall stability of the enzyme. The high thermal stability of KPC-2 allows destabilizing mutations that enhance catalysis to accumulate while the enzyme retains a folded, functional structure. Thus, the high stability of KPC-2 provides an evolutionary advantage to acquire multiple mutations and retain function as compared to other β-lactamase enzymes.

Introduction

Because of their broad-spectrum activity, safety and favorable pharmacokinetic properties [1], β-lactam antibiotics have been the drugs of choice to treat bacterial infections. While antibiotics have helped save millions of lives, the extensive use of these drugs has resulted in the emergence of antibiotic resistant bacterial strains. This problem is compounded by the ability of these organisms to acquire mutations or obtain genes encoding antibiotic-inactivating enzymes from other bacteria, thereby reducing the efficacy of drugs. Thus, treating antibiotic resistant bacterial infections is a complex clinical challenge [2].

The β-lactam antibiotics contain a characteristic four-membered β-lactam ring and act as covalent inhibitors of the essential transpeptidase enzymes known as penicillin binding proteins (PBP’s). The β-lactam antibiotics are classified into different groups based on their chemical structure [3]. The most clinically relevant classes are penicillins, cephalosporins and carbapenems (Fig 1). The penicillins and cephalosporins contain the β-lactam ring fused to a five or six-membered ring, respectively. The carbapenems consist of the β-lactam ring fused to a five-membered ring with a carbon atom replacing the sulfur at the C-1 position along with an unsaturated C2-C3 bond [4] (Fig 1). The presence of a 6-α-hydroxyethyl side-chain at the C-6 position of the β-lactam nucleus is a feature that distinguishes the carbapenems from the penicillins and cephalosporins that have a 6-β- or 7-β-acylamino side-chain in the same position, respectively [5] (Fig 1). In addition to being a structural distinguishing factor for the carbapenems, the 6-α-hydroxyethyl side-chain is also responsible for the broad-spectrum activity of the carbapenem antibiotics [6–8].

Resistance to the β-lactam antibiotics is mediated largely through β-lactamase enzymes. These enzymes hydrolyze the β-lactam amide bond rendering the antibiotic inactive. The β-lactamases have been grouped into four classes based on the primary sequence homology [9]. Enzymes belonging to classes A, C and D catalyze β-lactam hydrolysis using a catalytic serine, while class B consists of metallo-enzymes that function using one or two zinc ions [10]. The carbapenem antibiotics are considered the last line of therapy as they are resistant to the action of most β-lactamases [4]. In fact, carbapenems directly inhibit some β-lactamases by forming a
stable acyl-enzyme intermediate [6–8]. However, the increasing use of carbapenems has led to the emergence of carbapenem hydrolyzing β-lactamases [11]. Carbapenemase activity has been reported in class A, B and D β-lactamases [12]. In particular, resistance to carbapenems mediated by class A enzymes such as KPC-2, SME-1-3, IMI-1-2, SFC-1, NmcA, GES-2 and GES-4 to 6 poses a serious clinical threat [13]. Among these class A carbapenemases, KPC-2 is the most clinically important enzyme due to its prevalence in enteric bacteria [14]. Additionally, the presence of blacKPC-2 gene on the mobile transposon Tn4401 has facilitated its dissemination among Gram-negative bacteria [15].

Biochemical data have shown that KPC-2 is effective in hydrolyzing penicillins, cephalosporins and carbapenems. However, KPC-2 hydrolyzes cephemycins and ceftazidime poorly [16]. This broad-spectrum activity has resulted in severely limited treatment options leading to high fatality rates [14]. The problem of antibiotic resistance due to KPC enzymes has been compounded by the recent identification of a number of clinical variants of KPC-2. Currently, a total of 22 KPC variants have been annotated by Genbank and listed on the Lahey Clinic website (http://www.lahey.org/studies/other.asp#table1). In this study, we have characterized the variants KPC-3 to KPC-11 that possess 1 to 2 amino acid substitutions as compared to KPC-2. KPC-2 was first isolated in North Carolina, however the KPC variants have been isolated from Columbia, Italy, Spain, Puerto Rico, Scotland and Israel, indicating that this enzyme has rapidly disseminated throughout the world [17–22] (Fig 2). While KPC-2 was named after Klebsiella pneumoniae, these variants have been isolated from a variety of organisms including E. coli, Enterobacter cloacae, Actinobacter calcoaceticus-baumannii and Pseudomonas aeruginosa. [17–22] (Table 1).

Previous studies on KPC 3–6 and 9–11 have indicated that the amino acid substitutions associated with these variants result in increased resistance to ceftazidime while not affecting carbapenem resistance [17–22]. However, there is a need for more detailed biochemical analysis of the effect of these substitutions on the enzyme kinetics, stability and substrate profile of KPC-2. Additionally, no information about the substrate profiles is available for the variants KPC-7 and KPC-8. This information is essential to determine treatment regimens and for the design of new inhibitors for these enzymes. The results presented here indicate that the acquired mutations in KPC-2 expand its substrate profile by increasing catalytic efficiency for ceftazidime hydrolysis as much as 80-fold compared to wild-type KPC-2. This study also highlights the evolutionary advantage conferred to KPC-2 as compared to other class A β-lactamases due to its high structural stability and consequent ability to acquire destabilizing mutations while still maintaining a folded, active structure.
Results

Resistance profiles of KPC-2 variants expressed in *E. coli*

A total of nine KPC-2 variants, four variants differing from KPC-2 by a single amino acid and five variants differing from KPC-2 by two amino acids, were constructed by site-directed mutagenesis and introduced into *E. coli* RB791 cells (Materials and Methods). The same strain containing the expression plasmid that did not encode KPC-2 was used as a negative control. The effect of the mutations on the resistance profiles in *E. coli* was evaluated by determining MIC’s.

Table 1. Nucleotide polymorphisms and amino acid changes in variants as compared to KPC-2.

| Variant   | Nucleotide Change | Amino Acid Change | GenBank ID  |
|-----------|-------------------|-------------------|-------------|
| KPC-3     | 814 C -> T        | H274Y             | AF395881    |
| KPC-4     | 308 C -> G        | P104R             | AY700571    |
|           | 716 T -> G        | V240G             |             |
| KPC-5     | 308 C -> G        | P104R             | EU400222    |
| KPC-6     | 716 T -> G        | V240G             | EU555534    |
| KPC-7     | 147 G -> A        | M49I              | EU729727    |
|           | 814 C -> T        | H274Y             |             |
| KPC-8     | 716 T -> G        | V240G             | FJ34412     |
| KPC-9     | 814 C -> T        | H274Y             | FJ624872    |
| KPC-10    | 716 T -> C        | V240A             |             |
|           | 814 C -> T        | H274Y             |             |
| KPC-11    | 308 C -> T        | P104L             | HM066995    |

Fig 2. Positions of the variants residues included in this study on the KPC-2 enzyme. Positions that are substituted in variant enzymes are highlighted in red. The catalytic Ser70 is represented in yellow as a ball and stick model.

doi:10.1371/journal.ppat.1004949.g002
for each variant for a penicillin (ampicillin), an oxyimino-cephalosporin (ceftazidime) and the carbapenems, imipenem and meropenem (Table 2). Comparing the resistance profiles of the variant enzymes in an identical genetic background allows assignment of any changes in resistance to the corresponding single or double amino acid change, thus highlighting the role of specific residues in resistance to specific substrates (Table 2).

The MIC values of the four single amino acid variants, H274Y (KPC-3), P104R (KPC-5), V240G (KPC-6) and P104L (KPC-11) for ampicillin, imipenem and meropenem were within 2-fold of the KPC-2 MIC’s for these substrates. Interestingly, the H274Y (KPC-3) and V240G (KPC-6) substitutions resulted in a 4-fold increase in resistance to ceftazidime, while the P104R (KPC-5) substitution resulted in a 5-fold increase in resistance to ceftazidime. While the P104L (KPC-11) substitution did not display any change in resistance to ceftazidime, the other clinically observed single amino acid changes in KPC-2 result in an increase in resistance to ceftazidime while maintaining the resistance levels to penicillin and carbapenem antibiotics.

Similar to the single amino acid variants, the two amino acid variants did not display any significant differences for ampicillin, imipenem and meropenem MIC’s. The only exception was P104R:H274Y (KPC-10) that displayed a 4-fold and 3-fold decrease in MIC for ampicillin and meropenem, respectively. However, consistent with the observation for the single amino acid variants, each of the double amino acid variants resulted in an increase in resistance to ceftazidime. While P104R:H274Y (KPC-10) substitution resulted in a modest 4-fold increase in resistance to ceftazidime, V240A:H274Y (KPC-9), P104R:V240G (KPC-4), P104R:H274Y (KPC-10) and V240G:H274Y (KPC-8) resulted in 10-, 30-, 40- and 80-fold increases in ceftazidime MIC, respectively. The observation that these substitutions do not affect resistance to penicillin and carbapenem antibiotics while increasing resistance to ceftazidime implicates ceftazidime as the selective pressure for the acquisition of these variants in clinical isolates. Also, the dramatic increase in ceftazidime resistance in the two amino acid variants as compared to the single amino acid variants indicates a step-wise evolution with the acquisition increasing resistance with each amino acid variation.

### Steady-state enzyme kinetics

In order to have a biochemical correlate to the MIC data, each KPC variant was purified and steady-state kinetic parameters were determined for ampicillin, imipenem, meropenem and ceftazidime (Table 3). Consistent with the MIC data, the single amino acid changes did not result

| Table 2. Minimum inhibitory concentrations (MIC’s) of antibiotics for KPC variants. |
|-----------------------------|-------------------|-----------| -----------|-----------|
|                           | AMP (μg / mL)     | CAZ       | IMI        | MERO      |
| pTP123-empty               | 16                | 0.125     | 0.38       | 0.064     |
| pTP123-bla*KPC-2           | 128               | 0.38      | 1          | 0.38      |
| P104R                      | 64                | 2.0       | 0.75       | 0.25      |
| P104L                      | 64                | 0.5       | 0.75       | 0.25      |
| V240G                      | 128               | 1.5       | 1.0        | 0.25      |
| H274Y                      | 64                | 1.5       | 1          | 0.25      |
| P104R:V240G                | 64                | 12        | 1          | 0.25      |
| P104R:H274Y                | 32                | 16        | 1          | 0.125     |
| V240A:H274Y                | 128               | 4         | 1          | 0.19      |
| V240G:H274Y                | 128               | 32        | 2          | 0.25      |
| M49I:H274Y                 | 64                | 1.5       | 1          | 0.25      |

doi:10.1371/journal.ppat.1004949.t002
Table 3. Kinetic parameters of KPC variants.

| KPC Variant | AMP | IMI | MERO | CAZ |
|-------------|-----|-----|------|-----|
| KPC-2       | 50 ± 7 | 48 ± 3 | 3.8 ± 0.7 |
|             | 226 ± 68 | 252 ± 30 | 36 ± 16 |
|             | 0.23 ± 0.04 | 0.19 ± 0.03 | 0.11 ± 0.036 |
|             | 0.0008 ± 0.0002 |
| P104R       | 314 ± 15 | 28 ± 1 | 3.0 ± 0.4 |
| (KPC-5)     | 1407 ± 123 | 247 ± 22 | 53 ± 10 |
|             | 0.22 ± 0.01 | 0.12 ± 0.01 | 0.06 ± 0.004 |
|             | 0.009 ± 0.001 |
| P104L       | 12.8 ± 0.2 | 54 ± 4 | 2.5 ± 0.1 |
| (KPC-11)    | 136 ± 18 | 244 ± 31 | 35 ± 7 |
|             | 0.1 ± 0.01 | 0.22 ± 0.01 | 0.07 ± 0.01 |
|             | 0.002 ± 0.0002 |
| V240G       | 146 ± 4 | 27 ± 1 | 2.3 ± 0.07 |
| (KPC-6)     | 318 ± 11 | 172 ± 23 | 30 ± 4 |
|             | 0.46 ± 0.01 | 0.16 ± 0.02 | 0.08 ± 0.008 |
|             | 0.004 ± 0.0005 |
| H274Y       | 224 ± 16 | 34 ± 4 | 1.6 ± 0.1 |
| (KPC-3)     | 432 ± 48 | 108 ± 25 | 31 ± 8 |
|             | 0.52 ± 0.02 | 0.32 ± 0.04 | 0.05 ± 0.019 |
|             | 0.007 ± 0.0003 |
| P104R/V240G | 61 ± 5 | 21 ± 1 | 2.3 ± 0.04 |
| (KPC-4)     | 538 ± 84 | 157 ± 18 | 30 ± 3 |
|             | 0.12 ± 0.01 | 0.14 ± 0.01 | 0.08 ± 0.006 |
|             | 0.04 ± 0.002 |
| P104R:H274Y | 190 ± 3 | 31 ± 1 | 3.1 ± 0.07 |
| (KPC-10)    | 633 ± 42 | 211 ± 23 | 36 ± 1 |
|             | 0.3 ± 0.02 | 0.15 ± 0.01 | 0.08 ± 0.003 |
|             | 0.06 ± 0.01 |
| V240A:H274Y | 49 ± 4 | 27 ± 3 | 2.2 ± 0.2 |
| (KPC-9)     | 148 ± 24 | 113 ± 28 | 21 ± 2 |
|             | 0.33 ± 0.03 | 0.24 ± 0.04 | 0.1 ± 0.001 |
|             | 0.02 ± 0.004 |
| V240G:H274Y | 24 ± 3 | 24 ± 2 | 2.6 ± 0.2 |
| (KPC-8)     | 132 ± 23 | 110 ± 22 | 17 ± 2 |
|             | 0.18 ± 0.03 | 0.22 ± 0.02 | 0.16 ± 0.007 |
|             | 0.03 ± 0.003 |
| M49I:H274Y  | 225 ± 26 | 32 ± 1 | 3.0 ± 0.1 |
| (KPC-7)     | 411 ± 108 | 120 ± 1 | 31 ± 3 |
|             | 0.56 ± 0.08 | 0.26 ± 0.01 | 0.1 ± 0.006 |
|             | 0.006 ± 0.0002 |

doi:10.1371/journal.ppat.1004949.t003

In greater than 2-fold changes in catalytic efficiencies ($k_{cat}/K_m$) for ampicillin, imipenem and meropenem. The KPC variants, as well as the parental KPC-2, have high $K_m$ values for ceftazidime, and saturating levels of substrate cannot be obtained. However, the $k_{cat}/K_m$ value was determined under conditions where $[S] < < K_m$. Although the individual $k_{cat}$ and $K_m$ values could not be determined for ceftazidime hydrolysis by KPC-2 and the variants, a progress curve of the reaction with identical amounts of enzyme and substrate clearly shows the differences in activity of the enzymes (Fig 3). The KPC-2 enzyme hydrolyzes ceftazidime poorly with a catalytic efficiency of $8 \times 10^{-4} \mu M^{-1} sec^{-1}$. Consistent with the ceftazidime MIC results, the P104L mutant exhibited only a modest 2-fold increase in catalytic efficiency for ceftazidime hydrolysis. In contrast, 5-fold, 9-fold and 11-fold increases were observed for the V240G, H274Y and P104R mutants, respectively. Thus, while both the P104R and P104L substitutions are found in clinical isolates, arginine at this position seems to be preferred as compared to leucine for ceftazidime hydrolysis. Both the MIC and enzymatic data suggest that mutation of Pro104 to Arg results in the highest resistance levels to ceftazidime among the single amino acid variants due to the increased ability of this variant enzyme to hydrolyze ceftazidime as compared to KPC-2.
The catalytic efficiencies of the double mutants for ampicillin, imipenem and meropenem hydrolysis remained within 2-fold of the KPC-2 catalytic efficiencies for the same substrates. Except for P104R:H274Y (KPC-10), which displayed 4-fold and 3-fold decreases in MIC for ampicillin and meropenem, respectively, the enzyme kinetic data is in agreement with the MIC values for these substrates. For ceftazidime hydrolysis, M49I:H274Y (KPC-7) had the least impact with an 8-fold increase in catalytic efficiency as compared to KPC-2. The V240A:H274Y (KPC-9) and V240G:H274Y (KPC-8) variants exhibited 25- and 40-fold increases in catalytic efficiency while the P104R:V240G (KPC-4) and P104R:H274Y (KPC-10) double mutants had the largest impact with 50- and 75-fold increases, respectively, in catalytic efficiency for ceftazidime hydrolysis (Table 3). V240G:H274Y (KPC-8) exhibited the highest MIC for ceftazidime amongst all the mutants but did not display the highest catalytic efficiency. Thus, while the V240G:H274Y (KPC-8) mutant follows the overall trend of increasing activity, its catalytic efficiency does not directly correlate with the MIC value (Fig 4). This may reflect the fact that the MIC value is influenced by a number of variables including protein expression, stability and solubility in addition to catalytic efficiency. In summary, acquisition of the single and double substitutions associated with the variants allows KPC-2 to hydrolyze ceftazidime more efficiently and broadens the substrate profiles of the enzymes (Fig 3).

Additivity relationships between single and double amino-acid substitutions

The MIC and enzyme kinetics data indicate that the double mutants P104R:V240G (KPC-4), P104R:H274Y (KPC-10) and V240G:H274Y (KPC-8) show higher ceftazidime resistance and hydrolysis rates as compared to the constituting single mutants. When two substitutions are introduced into the enzyme together, their combined effect on catalysis may be additive or cooperative. For additive interactions, the fold change in the double mutant is expected to be the
product of the fold changes for the individual mutants. However, if the two substitutions interact (directly or indirectly), the fold change in the double mutant may be much higher (or lower) than that expected from the additive effects of the two single substitutions. To determine whether the interactions between P104R, V240G and H274Y are additive or cooperative for ceftazidime hydrolysis, the free energies ($\Delta\Delta G$) of the single and double mutants were calculated as described previously [23]. Briefly, the free energies associated with $k_{cat}/K_m$ values for KPC-2 and the single and double variants were calculated using Eq 2:

$$\Delta\Delta G = -RT\ln\left(\frac{k_{cat}/K_m}_{\text{mutant}}\right)/\left(\frac{k_{cat}/K_m}{\text{wild-type}}\right)$$

Table 4. Free energy values and additivity relationships between substituents for ceftazidime hydrolysis.

|          | $\Delta\Delta G$ | $\Delta\Delta i$ |
|----------|-----------------|-----------------|
| KPC2     | 0               | -               |
| P104R    | -0.63           | -               |
| V240G    | -0.42           | -               |
| H274Y    | -0.57           | -               |
| P104R:V240G | -1.02         | 0.03            |
| P104R:H274Y | -1.13         | 0.07            |
| V240G:H274Y | -0.95         | 0.04            |

Calculated from $k_{cat}/K_m$ of ceftazidime hydrolysis.

Fig 4. Bar graph comparing the MIC for ceftazidime (black) and catalytic efficiency for ceftazidime hydrolysis (gray). Both values are represented as fold changes compared to KPC-2.

doi:10.1371/journal.ppat.1004949.g004
Subsequently, the coupling free energy ($\Delta G_i$) was calculated using Eq 3:

$$\Delta \Delta G_{(x,y)} = \Delta \Delta G_{(x)} + \Delta \Delta G_{(y)} + \Delta G_i$$

(3)

Here $\Delta \Delta G_{(x,y)}$ represents the free energy difference between the wild-type and double mutant; $\Delta \Delta G_{(x)}$ and $\Delta \Delta G_{(y)}$ represent the differences in free energy between the wild-type and each single mutant, respectively, and $\Delta G_i$ represents the coupling free energy [24]. The KPC-2 enzyme is considered wild-type for the purposes of these comparisons. If the interactions between the single mutations are purely additive, then the coupling free energy is zero, $\Delta G_i = 0$; however, if the substitutions are non-additive (positive or negative cooperativity), then $\Delta G_i \neq 0$. The resulting $\Delta \Delta G$ values and $\Delta G_i$ values are summarized in Table 4. The $\Delta G_i$ values for P104R:V240G (KPC-4), P104R:H274Y (KPC-10) and V240G:H274Y (KPC-8) are 0.03, 0.07 and 0.04 respectively. These values are small compared to the $\Delta \Delta G$ values of the individual mutants and, therefore, the P104R, V240G and H274Y residues interact additively to facilitate ceftazidime hydrolysis. This means that the individual substitutions act independently and do not influence each other’s function when present in the double mutants. It also indicates that the order in which the individual mutations that make up a double mutant occur is not important.

**Determination of protein stability**

Substitutions close to the active site that alter enzyme function are often associated with a cost in terms of loss of protein stability [25–27]. Creating new, exposed hydrophobic surfaces or polar interactions that are satisfied only when substrate binds will be destabilizing to the enzyme in the absence of substrate. In order to determine any cost associated with the substitutions in the KPC variants, the thermal stability of each purified variant enzyme was determined using circular dichroism spectroscopy by monitoring $\alpha$-helix content at 222 nm with increasing temperature. The fit of the data and the $T_{m}$ values of the variants are summarized in Fig 5 and Table 5. Single substitutions close to the active site result in a 2.6 to 3.7°C loss in protein stability as compared to KPC-2. With the exception of M49I:H274Y (KPC-7), the double
Table 5. Melting temperatures of KPC-2 and variants.

|            | $T_m$ (°C) | $\Delta T_m$ (°C) |
|------------|------------|-------------------|
| KPC-2      | 66.5       |                   |
| P104R (KPC-5) | 62.8       | -3.7              |
| P104L (KPC-11) | 63.5       | -3.0              |
| V240G (KPC-6) | 63.0       | -3.5              |
| H274Y (KPC-3) | 63.9       | -2.6              |
| P104R:V240G (KPC-4) | 60.4       | -6.1              |
| P104R:H274Y (KPC-10) | 61.6       | -4.9              |
| V240A:H274Y (KPC-9) | 61.9       | -4.6              |
| V240G:H274Y (KPC-8) | 59.5       | -7.0              |
| M49I:H274Y (KPC-7) | 64.1       | -2.4              |

doi:10.1371/journal.ppat.1004949.t005

Evolution of KPC Carbapenemase Enzymes with Expanded Substrate Profile

Effect of mutations on protein expression levels

In addition to thermal stability and hydrolytic activity, protein expression levels in vivo also contribute to the overall resistance levels. Thus, to assess the effect of the single and double mutations on protein expression and the resulting effect on resistance levels, the steady-state expression levels of KPC-2 and the variant enzymes were measured (Fig 6). As expected, KPC-2, which has the highest $T_m$, also exhibits the highest expression level. The single mutants P104R, P104L and V240G showed a marginal decrease in expression while H274Y showed a 2-fold decrease. Among the double mutants, V240:H274Y and M49I:H274Y displayed the largest decrease in expression levels (3- and 4-fold respectively) while P104R:V240G and P104R:H274Y displayed a modest 2-fold decrease. The V240G:H274Y variant displayed the highest expression levels amongst all the double mutants. This provides an explanation for why this mutant showed the highest resistance to ceftazidime but not the highest catalytic efficiency (Fig 4). Taken together, the overall trends in expression levels are similar to the thermal stability results wherein the single and double mutants show a decrease in expression level as compared to KPC-2. The small magnitude of differences amongst mutants is not surprising considering that even the lowest $T_m$ observed among the KPC variants is 59.5°C, which is higher as compared to other class A β-lactamases such as TEM-1 β-lactamase [28].

In silico binding studies

Due to the absence of any structural data for the variants, molecular modeling was used to examine potential mechanisms by which the mutations increase the catalytic efficiencies for ceftazidime hydrolysis. Autodock Vina [29] was used to predict the binding conformation and interactions of ceftazidime with the wild-type and variant enzymes. The P104R:H274Y (KPC-10) variant was selected for study as it exhibited the largest increase in catalytic efficiency for
ceftazidime hydrolysis. The KPC-2 structure was used as a starting point and the P104R and H274Y substitutions were modeled based on predicted low energy conformations (Materials and Methods) [30]. Ceftazidime was then docked into the mutant structure using Autodock Vina and the top five results were compared. The binding conformation that displayed the β-lactam carbonyl oxygen positioned in the oxyanion hole and exhibited the highest number of hydrogen bonding interactions with ceftazidime was selected for further analysis. The analysis suggests that mutating residue 104 from proline to arginine promotes hydrolysis of ceftazidime by formation of an additional hydrogen bond between the guanidinium nitrogen of the arginine and the carboxyl functionality of the oxyimino group on ceftazidime. The docking results further suggest that substitution of histidine with tyrosine at position 274 results in the formation of a hydrogen bond between the tyrosine hydroxyl side chain and the amine functionality of the aminothiazole ring. (Fig 7). These interactions could result in increased catalytic efficiency through improved substrate binding or via transition state stabilization.

Discussion

Infections caused by bacteria producing KPC-2 β-lactamase have been associated with high rates of morbidity and mortality [14]. The presence of the KPC-2 enzyme and the consequent
carbapenem-resistance reduces treatment options [14]. In recent years, a number of variants of KPC β-lactamase have been identified from patient samples covering a wide geographic distribution [17–22]. In this study, amino acid substitutions associated with several clinically isolated KPC variants were examined in an identical plasmid and genetic background to evaluate if the substitutions result in altered patterns of hydrolysis and resistance to β-lactam antibiotics.

Fig 7. Molecular model of ceftazidime binding to the variant P104R:H274Y (KPC-10). The residues are represented in cyan and ceftazidime is represented in black. The dotted lines represent hydrogen bonds with the distances labeled.

doi:10.1371/journal.ppat.1004949.g007
The clinically-identified single and double mutants of KPC-2 represent evolved versions of KPC-2 with an expanded substrate profile that includes the oxyimino-cephalosporin ceftazidime. Importantly, these variants do not exhibit substantially reduced activity towards carbapenems, creating a further threat to antibiotic therapy.

A broadening substrate profile through the acquisition of mutations has previously been observed for the TEM and CTX-M β-lactamases [27,31,32]. Interestingly, residue 104 plays a crucial role in conferring ceftazidime hydrolyzing ability to TEM β-lactamase [31,33]. The E104K mutation in TEM-1 results in a 4-fold increase in MIC for ceftazidime and a 50-fold increase in catalytic efficiency for ceftazidime hydrolysis [33]. Similarly, in the case of CTX-M β-lactamases, a D240G substitution increases the ceftazidime MIC by 8-fold due to a 10-fold increase in catalytic efficiency of ceftazidime hydrolysis [34]. The improved ceftazidime hydrolyzing ability of KPC-2 variants containing substitutions at residues 104 and 240 reveals that this is a common strategy among class A enzymes for expanding the substrate spectrum to ceftazidime.

Interestingly, the H274Y substitution and the combinations such as P104R:V240G (KPC-4), P104R:H274Y (KPC-10), and V240G:H274Y (KPC-8) have not been associated with increased ceftazidime hydrolysis in other class A β-lactamases, suggesting these mutational pathways to ceftazidime resistance are unique to KPC-2. Modeling studies suggest that hydrogen bonds with amino acid residues at position 104 and 274 and substrate improve the catalytic efficiency of ceftazidime hydrolysis. Since glycine does not have a side-chain, modeling was not performed; however, substitution of residue 240 to glycine or alanine may expand the active site or increase flexibility in the region to accommodate ceftazidime.

A number of studies on class A β-lactamases as well as other enzymes indicate that mutations that alter function often lead to decreased stability [25–27,35,36]. This function-stability trade-off is attributed to the increased active site strain resulting from the increased activity associated with a gain-of-function substitution [27]. The observed decrease in stability of the single and double mutants of KPC-2 is consistent with a function-stability trade-off. This is illustrated in Fig 8 by a plot of the log of the catalytic efficiency for ceftazidime hydrolysis versus the thermal stability of the KPC mutants, which reveals a strong correlation between the gain of function and loss of stability (R^2 = 0.8). Thus, there is a clear inverse relationship between function (catalytic efficiency) and stability for the KPC group of enzymes studied here.

The stability measurements performed in this study reveal that KPC-2 and its variants are more stable than other common class A enzymes. For example, the T_m of KPC-2 (66.5°C) is 15°C higher than that of TEM-1 (51.5°C) and CTX-M-14 (51°C) [28,37]. When TEM-1 acquires a single substitution such as G238S (TEM-19) that improves its oxyimino-cephalosporins hydrolyzing activity, it results in a 4.5°C decrease in T_m to 47°C [27]. The low stability of the TEM G238S mutant constrains the acquisition of further substitutions to those that do not significantly lower stability further or that rescue stability in the form of a global stabilizer substitution such as M182T [27,38]. The high stability of KPC-2 could serve as a buffer for the acquisition of further substitutions as reflected by the fact that the KPC-2 single mutants, although less stable than KPC-2, still retain higher stability than both wild type TEM-1 and CTX-M-14. Thus, single substitution mutants of KPC-2 have sufficient stability that they can acquire a second, functionally beneficial but destabilizing substitution and still fold into an active enzyme. In fact, even the double substitution mutants of KPC-2 retain higher stability than both the TEM-1 and CTX-M-14 enzymes. The immunoblotting experiments of KPC-2 and the variants reveals the loss in stability is associated with decreased expression levels, however, functional enzyme is still produced and provides for increased ceftazidime resistance as indicated by MIC values. Therefore, the high stability of KPC-2 may be an evolutionary advantage over other class A enzymes that allows it to acquire multiple destabilizing substitutions that increase catalysis.
The evolutionary advantage of a highly stable enzyme as a starting point for the selection of variants with altered function has been demonstrated for several systems in directed evolution experiments [39]. For example, the presence of the M182T stabilizing substitution in TEM-1 reduces the number of random single amino acid substitutions that inactivate the enzyme by one-third [40]. Similar observations have been made with a P450 enzyme as well as a thermophilic chorismate mutase [41,42]. Thus, excess stability provides a buffer for an enzyme to absorb mutations that are catalytically beneficial but are associated with a stability cost, such as the KPC mutations characterized in this study.

To date 22 KPC variants have been identified. This study provides a detailed analysis of 9 variants. Besides these variants, a recent study characterized KPC-15, which exhibits increased ceftazidime activity and has the P104R, V240G, H274Y mutations as well as A120L and G147K substitutions [43]. Our results suggest that the P104R, V240G and H274Y substitutions contribute strongly to the ceftazidime hydrolysis activity of this variant. Of the remaining uncharacterized variants, KPC-13 (GenBank: HQ342889) and KPC-19 (GenBank: KJ775801) have the H274Y mutation in conjunction with D92G and N293T substitutions, respectively. Based on the presence of the H274Y mutation, we would speculate that these variants have increased ceftazidime hydrolysis activity. However, it is difficult to speculate on the roles of D92G and N293T considering their position is far away from the active site. KPC-14 (GenBank: JX524191), KPC-16 (GenBank: KC465199), KPC-17 (GenBank: KC465200) and KPC-22 (GenBank: KM379100), each possess unique mutations that have not been characterized. Additionally, while KPC-18, KPC-20 and KPC-21 have been identified and annotated a Genbank ID, their sequences are not yet available for analysis (http://www.lahey.org/studies/other.asp#table1).

As described here, the KPC enzymes have evolved substitutions that result in increased ceftazidime hydrolysis. Yet, the number of KPC variant enzymes identified to date is an order of magnitude less than the number of TEM variant extended spectrum β-lactamases (ESBLs) known (~220). One reason for this is that TEM was identified in 1963 and TEM ESBLs were first identified in 1983 while the KPC-2 was identified in the late 1990s and the first variants in 2001.
Thus, there has been less time and opportunity for the evolution of KPC variants. It is also possible that the increased stability of the KPC variants relative to TEM variants results in less selective pressure for second site substitutions that stabilize KPC such as are commonly observed among TEM ESBLs; for example M182T [38]. This would lead to less diversification of the KPC enzymes versus the TEM enzymes due to the accumulation of fewer stabilizing substitutions.

The KPC enzymes represent a versatile and adaptable group. This study highlights how KPC-2 is evolving under the pressure of current antibiotic therapy towards increased resistance to the oxyimino-cephalosporin, ceftazidime. The V240G:H274Y (KPC-8) double mutant provides high-level resistance to all β-lactam classes including penicillins, cephalosporins and carbapenems antibiotics. The stability of this double mutant is 8°C lower than KPC-2, however, it is still substantially more stable than other class A enzymes. Therefore, one can expect the evolution of more KPC-variants with altered substrate profiles.

**Materials and Methods**

**Bacterial strains and plasmids**

*E. coli* K12 XL1-Blue strain (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIqZ ΔM15 Tn10 (Tet’)]) was obtained from Stratagene (La Jolla, CA) and used in site-directed mutagenesis experiments. The *E. coli* RB791 strain was used for protein expression, purification and MIC determinations [45]. The *bla*KPC-2 gene was inserted in the previously described pTP123 plasmid [46]. The resulting plasmid was used to express and purify the KPC-2 enzyme and also used as a template for site-directed mutagenesis and subsequent expression of mutant enzymes in *E. coli* RB791 [47].

**Site-directed mutagenesis**

All KPC-2 mutants were created using the QuikChange kit (Stratagene, La Jolla, CA). Oligonucleotides were obtained from Integrated DNA Technologies (Coralville, IA). The following is the list of primers used to introduce mutations (underlined) into pTP123 KPC-2:

- P104R: CAAAAATGCGCTGGTTCGCTGGTCACCCATCTC
- P104L: CAAAAATGCGCTGGTTCTGTGGTCACCCATCTC
- V240A: CGGAACCTGCGGAGCGTATGGCACGGCAAATG
- V240G: CGGAACCTGCGGAGGGTATGGCACGGCAAATG
- H274Y: CAAGGATGACAAGTACAGCGAGGCCGTCATC
- M49I: CGGTGTGTACGCGATAGATACCGGCTCAG

**Minimum inhibitory concentration (MIC) determinations**

Minimum inhibitory concentrations (MIC’s) for *E. coli* strain RB791 containing the KPC mutants was determined for imipenem, meropenem and ceftazidime using Etest strips (Ab Biodisk, Sweden) according to the manufacturers recommendations. The MIC’s of the variants for ampicillin were determined using the broth dilution method in a 100-well microtiter format. Overnight cultures of the variants were diluted into wells containing two-fold dilutions of ampicillin in a total volume of 300 μL LB broth. The plate was allowed to incubate overnight at 37°C with continuous shaking and scored for visible growth to determine the MIC.

**Protein purification**

The relevant *bla*KPC variant gene in plasmid pTP123 was transformed into *E. coli* RB791 cells and colonies were selected on LB agar containing 12.5 μg/mL chloramphenicol. A single colony was used to inoculate 20 mL LB containing 12.5 μg/mL chloramphenicol and allowed to grow
overnight at 37°C. The overnight culture was added to 1 L LB broth containing 12.5 μg/mL chloramphenicol at a final dilution of 1:100 and subsequently allowed to grow to OD_{600} 0.7 at 37°C. Protein expression was induced by addition of 1 M IPTG to a final concentration of 0.2 mM and the cultures were grown at 23°C overnight. The cells were harvested by centrifugation at 4000 x g for 20 minutes and the pellet frozen for at least 1 hour at -80°C. To release the periplasmic contents, the pellet was resuspended in 50 mL of 10 mM Tris-HCl buffer, pH 8.0 containing 1 tablet of Complete Protease Inhibitor Cocktail (Roche Diagnostics Corporation, Indianapolis, IN) and incubated on ice for 1 hour. Subsequently, osmotic shock was initiated by addition of 50 mL of cold, sterile water. The insoluble material was pelleted by centrifugation at 10,000 g for 1 hour. The supernatant was filtered and passed through a HiTrap SP column (GE Healthcare, Piscataway, NJ). The P104R, P104R:V240G and P104R:H274Y mutants bound the column at pH 8.0 and were eluted using a NaCl gradient. The remaining enzyme variants were bound to the column by adjusting the buffer to pH 5.5 using MES acid and subsequently they were eluted using a NaCl gradient. The purity of the β-lactamase containing fractions was determined using SDS-PAGE and the pooled fractions were concentrated and subjected to size exclusion chromatography using a HiLoad Superdex 75 column (GE Healthcare, Piscataway, NJ). Protein concentrations were determined by measuring the optical density at 280 nm and using the following extinction coefficients for respective proteins: 39,545 M^{-1}cm^{-1} was used for KPC-2, KPC-4, KPC-6, KPC-11; 41,035 M^{-1}cm^{-1} for KPC-3, KPC-7, KPC-8, KPC-9, KPC-10 and 39,420 M^{-1}cm^{-1} for KPC-5. All the extinction coefficients were calculated using the ‘ProtParam’ tool from the Swiss Institute of Bioinformatics online resource portal [48].

Enzyme kinetics

Michaelis-Menten kinetic parameters for KPC-2 and the variant enzyme-substrate pairs were determined at 25°C in 50 mM sodium phosphate buffer, pH 7.0, containing 0.1 mg/mL BSA using variable amounts of enzyme depending on the enzyme-substrate pair. The initial velocities of β-lactam hydrolysis were measured on a Beckman-Coulter spectrophotometer model DU-800 (Fullerton, CA) using the following extinction coefficients: imipenem, Δε_{295} = -9000 M^{-1}cm^{-1}; meropenem, Δε_{295} = -10,940 M^{-1}cm^{-1}; ceftazidime Δε_{295} = -7600 M^{-1}cm^{-1}; ampicillin, Δε_{215} = -900 M^{-1}cm^{-1}. GraphPad Prism 5 was used to obtain the steady-state parameters by non-linear least squares fit of the data to the Michaelis-Menten equation \( v = \frac{k_{cat}[S]}{K_m + [S]} \). The velocity of ceftazidime hydrolysis could not be saturated by measurable concentrations due to a high \( K_m \). Thus, the second order rate constant at steady-state, \( k_{cat}/K_m \), was determined by fitting the progress curves to the equation \( v = \frac{k_{cat}}{K_m}[E][S] \), where \([S] << K_m \) (eq. 1).

Thermal denaturation

Thermal denaturation experiments were performed as described previously [28]. In short, the thermal stability of the KPC variants was measured on a Jasco J-815 circular dichroism spectropolarimeter (Jasco, Essex, UK) coupled with a Peltier effect temperature controller. A total of 0.15 mg/mL of enzyme in 50 mM sodium phosphate buffer, pH 7.0, was placed in a 0.1 cm quartz cuvette and unfolding of the proteins was observed at 222 nm by heating the samples from 40°C to 80°C in 0.1°C increments at a rate of 1°C min^{-1}. The melting temperature (\( T_m \)) is the temperature mid-point of protein unfolding and was determined by fitting the data to a single Boltzmann model.

Protein expression levels

To assess the effect of the single and double mutations on KPC expression levels, a western blot was performed. Overnight cultures of RB791 cells expressing KPC-2 and the variants were
diluted 1:100 into LB broth containing 12.5 μg/mL chloramphenicol. Cells were grown to OD_{600} = 0.6 at 37°C and 5 mL culture was pelleted by centrifugation at 13,000 rpm. The periplasmic contents were released by resuspending the cells in 100 μl of 10 mM Tris pH 8.0 buffer, containing 20% sucrose and osmotic shock induced by adding 100 μl of cold sterile water. The insoluble fraction was separated by centrifugation [23]. Total protein concentrations were determined using the Bradford protein assay. 1 μg of total periplasmic proteins were loaded in each well. Purified KPC-2 enzyme was used as a positive control and periplasmic fraction from cells containing the empty vector was used as a negative control. The blot was probed using polyclonal anti-KPC antibody as the primary antibody and anti-rabbit, horseradish peroxidase (HRP) conjugated antibody as the secondary antibody. SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) was used as substrate for the secondary antibody. Band intensities were quantified using ImageJ software.

Molecular modeling

In the absence of structural data, molecular modeling was performed to evaluate the effects of the mutations on KPC-2 β-lactamase. A molecular model of the P104R:H274Y was created by mutating the KPC-2 structure [30] (PDB ID: 2OV5) in silico using the Dunbrack rotamer library as a part of the UCSF Chimera software [49,50]. The Dunbrack backbone-dependent rotamer library predicts the conformation of the amino acid side-chain based on the global energy minimum of the protein. A PDB file for ceftazidime was created using the CORINA software, Molecular Networks Gmbh, Earlangen, Germany. Ceftazidime was then docked into this model to predict the Michaelis-Menten complex using the Autodock Vina docking method as described previously [29,51]. Briefly, the protein was prepared for docking by adding polar hydrogen atoms using AutoDockTools. The grid box was centered on the catalytic Ser-70 residue and the dimensions of the docking space (26 x 30 x 22 Å) were adjusted to include the entire catalytic site. Of the 5 results, the model with ceftazidime positioned in the binding conformation with the β-lactam carbonyl directed into the oxyanion hole and displaying the largest number of hydrogen bond and hydrophobic interactions was chosen for further analysis.

Acknowledgments

The authors thank Dr. Paul Leonard, Dr. Todd Link and the Center for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center for the use of their Circular Dichroism instrument. The authors also thank Dr. Hardik I. Parikh for his insights for the molecular modeling experiments and Dr. Hiram Gilbert for comments on the manuscript.

Author Contributions

Conceived and designed the experiments: SCM TP. Performed the experiments: SCM KR TP. Analyzed the data: SCM KR TP. Contributed reagents/materials/analysis tools: SCM KR. Wrote the paper: SCM TP.

References

1. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006; 14: 413–420. PMID: 16876996
2. Arias CA, Murray BE. Antibiotic-Resistant Bugs in the 21st Century—A Clinical Super-Challenge. N Engl J Med. 2009; 360: 439–443. doi: 10.1056/NEJMep0804651 PMID: 19179312
3. Kong KF, Schneper L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2010; 118: 1–36. doi: 10.1111/j.1600-0463.2009.02563.x PMID: 20041868
4. Papp-Walace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: Past, Present, and Future. Antimicrob Agents Chemother. 2011; 55: 4943–4960. doi: 10.1128/AAC.00296-11 PMID: 21859938
Evolution of KPC Carbapenemase Enzymes with Expanded Substrate Profile

5. Birbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med. 1985; 78: 3–21. PMID: 3925777

6. Maveyraud L, Mourey L, Kotra LP, Pedelaq J-D, Guillet V, Mobashery S, et al. Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A beta-Lactamases from the Antibiotic-Resistant Bacteria. J Am Chem Soc. 1998; 120: 9748–9752.

7. Nukaga M, Bethel CR, Thomson JM, Hujer AM, Distler A, Anderson VE, et al. Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J Am Chem Soc. 2008; 130: 12656–12662. doi: 10.1021/ja7111116 PMID: 18761444

8. Fonseca F, Chudýk EI, van der Kamp MW, Correia A, Mulholland AJ, Spencer J. The basis for carbapenem hydrolysis by class A beta-lactamases: a combined investigation using crystallography and simulations. J Am Chem Soc. 2012; 134: 18275–18285. doi: 10.1021/ja304460j PMID: 23030300

9. Helfand MS, Bonomo RA. beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord. 2003; 3: 9–23. PMID: 12570729

10. Crowder MW, Spencer J, Vila AJ. Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res. 2006; 39: 721–728. PMID: 17042472

11. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010; 300: 371–379. doi: 10.1016/j.ijmm.2010.04.005 PMID: 20537585

12. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010; 36 Suppl 3: S8–14. doi: 10.1016/S0924-8579(10)70004-2 PMID: 21129630

13. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases: a snapshot of extended-spectrum beta-lactamases throughout the world. J Clin Microbiol. 2012; 50: 1632–1639. doi: 10.1128/JCM.06115-11 PMID: 22322349

14. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9: 228–236. doi: 10.1016/S1473-3099(09)70054-4 PMID: 19324295

15. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase alphaKPC gene. Antimicrob Agents Chemother. 2008; 52: 1257–1263. doi: 10.1128/AAC.01451-07 PMID: 18227185

16. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 45: 1151–1161. PMID: 11257029

17. Hidalgo-Grass C, Warburg G, Temper V, Benenson S, Moses AE, Block C, et al. KPC-9, a novel carbapenemase from clinical specimens in Israel. Antimicrob Agents Chemother. 2012; 56: 6057–6059. doi: 10.1128/AAC.01515-12 PMID: 22964687

18. Larmoureaux TL, Frase H, Antunes NT, Vakulenko SB. Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6. Antimicrob Agents Chemother. 2012; 56: 6006–6059. doi: 10.1128/AAC.01383-12 PMID: 22908150

19. Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, et al. Using nucleic acid microarrays to perform molecular epidemiology and detect novel beta-lactamases: a snapshot of extended-spectrum beta-lactamases throughout the world. J Clin Microbiol. 2012; 50: 1632–1639. doi: 10.1128/JCM.06115-11 PMID: 22322349

20. Robledo IE, Aquino EE, Sante ML, Santana JL, Otero DM, Leon CF, et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother. 2010; 54: 1355–1357. doi: 10.1128/AAC.00899-09 PMID: 20038618

21. Wolter DJ, Kuriel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother. 2009; 53: 557–562. doi: 10.1128/AAC.00734-08 PMID: 19015357

22. Woodford N, Tiernor PM Jr., Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother. 2004; 48: 4793–4799. PMID: 15561858

23. Adamski CJ, Cardenas AM, Brown NG, Horton LB, Sankanara B, Prasad BV, et al. Molecular Basis for the Catalytic Specificity of the CTX-M Extended-Spectrum beta-Lactamases. Biochemistry. 2014; 54: 447–458. doi: 10.1021/bi501195g PMID: 25489790

24. Wells JA. Additivity of mutational effects in proteins. Biochemistry. 1990; 29: 8509–8517. PMID: 2271534

25. Schreiber G, Buckle AM, Fersht AR. Stability and function: two constraints in the evolution of barstar and other proteins. Structure. 1994; 2: 945–951. PMID: 7866746

26. Shoichet BK, Baase WA, Kuroki R, Matthews BW. A relationship between protein stability and protein function. Proc Natl Acad Sci USA. 1995; 92: 452–456. PMID: 7851309
27. Wang X, Minasov G, Shoichet BK. Evolution of an Antibiotic Resistance Enzyme Constrained by Stability and Activity Trade-offs. J Mol Biol. 2002; 320: 85–95. PMID: 12079336
28. Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T. Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM \( \beta \)-lactamases. J Mol Biol. 2010; 404: 832–846. doi: 10.1016/j.jmb.2010.10.008 PMID: 20955714
29. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31: 455–461. doi: 10.1002/jcc.21334 PMID: 19499576
30. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A \( \beta \)-lactamases. Biochemistry. 2007; 46: 5732–5740. PMID: 17441734
31. Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ, et al. Substitution of lysine at position 104 or 240 of TEM-1\( \beta \)-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry. 1991; 30: 3179–3188. PMID: 1901218
32. Cantu C 3rd, Huang W, Palzkill T. Cephalosporin substrate specificity determinants of TEM-1 \( \beta \)-lactamase. J Biol Chem. 1997; 272: 29144–29150. PMID: 9360991
33. Petit A, Maveyraud L, Lenfant F, Samama JP, Labia R, Masson JM. Multiple substitutions at position 104 of \( \beta \)-lactamase TEM-1: assessing the role of this residue in substrate specificity. Biochem J. 1995; 305 (Pt 1): 33–40. PMID: 7826350
34. Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, et al. Effect of D240G substitution in the \( \beta \)-Lactamases. J Mol Biol. 2010; 404: 832–846. doi: 10.1016/j.jmb.2010.10.008 PMID: 20955714
35. Meiering EM, Serrano L, Fersht AR. Effect of active site residues in barnase on activity and stability. J Mol Biol. 1999; 295 (3): 671–685. doi: 10.1006/jmbi.1999.3624. PMID: 10418215
36. Bloom JD, Arnold FH. In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A. 2000; 97: 7547–7552. doi: 10.1073/pnas.97.14.7547 PMID: 10853885
37. Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T. Multiple Global Suppressors of Protein Stability Defects Facilitate the Evolution of Extended-Spectrum TEM \( \beta \)-Lactamases. J Mol Biol. 2010; 404: 832–846. doi: 10.1016/j.jmb.2010.10.008 PMID: 20955714
38. Meiering EM, Serrano L, Fersht AR. Effect of active site residues in barnase on activity and stability. J Mol Biol. 1992; 225: 585–589. PMID: 1602471
39. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M \( \beta \)-lactamases: extended spectrum activities from increased mobility and decreased stability. J Mol Biol. 2005; 348: 349–362. PMID: 15811373
30. Huang W, Palzkill T. A natural polymorphism in \( \beta \)-lactamase is a global suppressor. Proc Natl Acad Sci U S A. 1997; 94: 8801–8806. PMID: 9238058
31. Bloom JD, Arnold FH. In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A. 2009; 106 Suppl 1: 9995–10000. doi: 10.1073/pnas.0901522106 PMID: 19528653
32. Bloom JD, Silberg JJ, Wilke CO, Drummond DA, Adami C, Arnold FH. Thermodynamic prediction of protein neutrality. Proc Natl Acad Sci U S A. 2005; 102: 606–611. PMID: 15644440
33. Besenmatter W, Kast P, Hilvert D. Relative tolerance of mesostable and thermostable protein homologs to extensive mutation. Proteins. 2007; 66: 500–506. PMID: 17096428
34. Bloom JD, Labhavikul ST, Otey CR, Arnold FH. Protein stability promotes evolvability. Proc Natl Acad Sci U S A. 2008; 103: 5869–5874. PMID: 1861913
35. Wang D, Chen J, Yang L, Mou Y, Yang Y. Phenotypic and enzymatic comparative analysis of the KPC variants, KPC-2 and its recently discovered variant KPC-15. PLoS One. 2014; 9: e111491. doi: 10.1371/journal.pone.0111491 PMID: 25360633
36. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965; 208: 239–241. PMID: 5326330
37. Amann E, Brosius J, Plasche M. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli. Gene. 1983; 25: 167–178. PMID: 6363212
38. Metcosino J, Rudgers G, Gilbert H, Palzkill T. Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of \( \beta \)-lactamases. J Biol Chem. 1999; 274: 2394–2400. PMID: 9891008
39. Bloom JD, Chow DC, Palzkill T. BLIP-II is a highly potent inhibitor of Klebsiella pneumoniae carbapenemase (KPC-2). Antimicrob Agents Chemother. 2013; 57: 3398–3401. doi: 10.1128/AAC.00215-13 PMID: 23587951
40. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Cesari G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012; 40: W597–603. doi: 10.1093/nar/gks400 PMID: 22661580
49. Dunbrack RL Jr. Rotamer libraries in the 21st century. Curr Opin Struct Biol. 2002; 12: 431–440. PMID: 12163064

50. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605–1612. PMID: 15264254

51. Stojanoski V, Chow DC, Hu L, Sankaran B, Gilbert HF, Prasad BV, et al. A Triple Mutant in the Ω-loop of TEM-1 β-Lactamase Changes the Substrate Profile via a Large Conformational Change and an Altered General Base for Catalysis. J Biol Chem. 2015; 290: 10382–10394. doi:10.1074/jbc.M114.63438 PMID: 25713062